A meta-analysis assessing the role of ICIs (nivolumab, pembrolizumab and atezolizumab) as second-line therapy in EGFR-driven advanced NSCLC, including three trials (CheckMate 057, KEYNOTE-010 and POPLAR study), concluded that EGFR-mutant patients didn’t benefit from ICIs over docetaxel in terms of OS (91). This evidence concerns the gene EGFR and non-small cell lung carcinoma.